- Waller deemed competent to stand trial (1/11/17)5
- Young Elvis impersonator from Bernie performs on 'Ellen DeGeneres Show' (1/12/17)
- 113 drug tests at Jackson High net one instance of illicit usage (1/11/17)14
- Two subjects of interest in 1992 homicide to take polygraph tests (1/15/17)6
- Two men shot after argument; houses also struck by bullets (1/12/17)21
- Imo's Pizza will be added to Rhodes 101 convenience store in Jackson (1/10/17)16
- Cape SportsPlex contractor offers a look at the project (1/15/17)13
- Juvenile accused of stealing, damaging playground statue (1/9/17)25
- Two Cape men recovering after shooting (1/13/17)
- Business notebook: Faithfully Fed aims for more than just food (1/9/17)4
Botox maker refuses FDA demand to pull ads
IRVINE, Calif. -- The maker of Botox, the wrinkle-smoothing botulism toxin, is refusing a demand by the Food and Drug Administration to pull ads the agency says are misleading.
Allergan Inc. reacted angrily Monday to the FDA's order to "immediately cease distribution" of advertisements and brochures.
The FDA said the company's multi-million dollar ad campaign does not specify the particular wrinkles Botox is approved to treat, in violation of federal law.
The agency also said the Botox brochure misleads patients about the duration of a wrinkle-reducing injection, which is usually about four months. The Allergan Web site for physicians also led to confusion on dilution of the Botox solution, said Mary Malarkey, director of case management for the FDA's Center for Biologics Evaluation and Research.
Allergan said it will not pull the advertisements or the brochure.
"We strongly disagree on all points," said Allergan spokeswoman Christine Cassiano, adding that the company "worked diligently" with the agency to produce accurate materials.
Cassiano said the FDA has never previously indicated there was a problem.
The company has 10 days to provide a written response to the FDA demand, which is one step short of a federal warning in which the FDA outlines enforcement action to the Justice Department.
Botulinum toxin type A, or Botox, was approved by the FDA this year for use on a specific wrinkle that develops between the eyebrows and the forehead.